Minerva Neurosciences | NERV - Pre Tax Profit

Stock Price
6.18
Daily Change
0.14 2.32%
Monthly
-0.80%
Yearly
231.37%
Q1 Forecast
7.31

Minerva Neurosciences reported $22.51M in Pre-Tax Profit for its fiscal quarter ending in September of 2024.





Pre Tax Profit Change Date
Acadia Pharmaceuticals USD 26.32M 18.28M Dec/2025
Adma Biologics USD 61.59M 14.07M Dec/2025
ALKERMES USD 100.74M 4.1M Sep/2025
Alterity Therapeutics Limited AUD -4.74M 3.53M Dec/2024
AstraZeneca USD 3.24B 117M Sep/2025
BioCryst Pharmaceuticals USD 248.02M 235.89M Dec/2025
Bristol-Myers Squibb USD 3.11B 1.34B Sep/2025
Cipla INR 11.69B 6.85B Dec/2025
Clal Biotechnology ILS 86.82M 17.9M Dec/2022
Compugen USD 56.84M 63.78M Dec/2025
CSL USD 2.61B 1.21B Dec/2025
Eli Lilly USD 7.23B 456M Sep/2025
Esperion Therapeutics USD 63.67M 95M Dec/2025
GlaxoSmithKline GBP 1.23B 1.23B Dec/2025
Grifols EUR 257.85M 190.87M Dec/2024
Halozyme Therapeutics USD 218.96M 14.02M Sep/2025
Ionis Pharmaceuticals USD -228M 99M Dec/2025
J&J USD 4.97B 2.53B Dec/2025
Merck USD 6.74B 22M Sep/2025
Minerva Neurosciences USD 22.51M 30.74M Sep/2024
Neurocrine Biosciences USD 239.4M 52.4M Dec/2025
Novartis USD 4.64B 445M Dec/2025
Novavax USD 17.9M 220.94M Dec/2025
Pfizer USD 3.33B 290M Sep/2025
Roche Holding CHF 4.79B 3.01B Jun/2025
Sanofi EUR -1.16B 5.5B Dec/2025
Takeda JPY 133.86B 105.69B Dec/2025
Vanda Pharmaceuticals USD -22.92M 16.68M Dec/2024